Piper Sandler on Soleno Therapeutics Inc. (SLNO): 'VYKAT XR Approved With Spot Clean Label & Lucrative Pricing'
Tweet Send to a Friend
Piper Sandler analyst Yasmeen Rahimi reiterated an Overweight rating and $93.00 price target on Soleno Therapeutics Inc. (NASDAQ: SLNO).The analyst ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
